Moderna 疫苗经研究对英国和南非病毒有效

s
storz
楼主 (北美华人网)
https://investors.modernatx.com/news-releases/news-release-details/moderna-covid-19-vaccine-retains-neutralizing-activity-against
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 25, 2021-- Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively. The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants. A six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective. This study was conducted in collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases(NIAID), part of the National Institutes of Health (NIH). The manuscript has been submitted as a preprint to bioRxiv and will be submitted for peer-reviewed publication.
The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 µg dose is expected to be protective against emerging strains detected to date. Nonetheless, Moderna today announced its clinical strategy to proactively address the pandemic as the virus continues to evolve. First, the Company will test an additional booster dose of its COVID-19 Vaccine (mRNA-1273) to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. Second, the Company is advancing an emerging variant booster candidate (mRNA-1273.351) against the B.1.351 variant first identified in the Republic of South Africa. The Company is advancing mRNA-1273.351 into preclinical studies and a Phase 1 study in the U.S. to evaluate the immunological benefit of boosting with strain-specific spike proteins. Moderna expects that its mRNA-based booster vaccine (whether mRNA-1273 or mRNA-1273.351) will be able to further boost neutralizing titers in combination with all of the leading vaccine candidates.
For the B.1.1.7 variant, neutralizing antibody titers remained high and were generally consistent with neutralizing titers relative to prior variants. No significant impact on neutralization was observed from either the full set of mutations found in the B.1.1.7 variant or from specific key mutations of concern. Although these mutations have been reported to lessen neutralization from convalescent sera and to increase infectivity, sera from the Phase 1 participants and NHPs immunized with mRNA-1273 were able to neutralize the B.1.1.7 variant to the same level as prior variants.
For the B.1.351 variant, vaccination with the Moderna COVID-19 Vaccine produces neutralizing antibody titers that remain above the neutralizing titers that were shown to protect NHPs against wildtype viral challenge. While the Company expects these levels of neutralizing antibodies to be protective, pseudovirus neutralizing antibody titers were approximately 6-fold lower relative to prior variants. These lower titers may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains.

n
nobully
回复 1楼storz的帖子
好消息
d
dan1313
好消息
8
85打酱油
太好了,顺便说今早收到儿医的邮件,说针对儿童的trial也在进行中,希望早点能成功
s
stephilosphy
好消息,下周打第二针
l
little_racoon
没那么乐观,血清的中和能力下降6倍,还是很危险的。之前Rockfeller用带了南非毒株上面三个突变的假病毒做出来的结果是下降3倍,看来带有全部突变的毒株逃逸能力更强。我觉得很多免疫反应差一点的疫苗对南非突变很可能已经没多少效果了。。。
Moderna的疫苗起点很高,中和能力是康复血清的4倍,所以就算下降了还是有保护能力的,再加上T细胞免疫,短期内的保护效果应该还看得过去。但是体液免疫会随时间衰退,保护能力会慢慢下降,T细胞免疫能够避免重症但是很难完全预防有症状感染。现在Moderna已经开始做针对南非变种的booster shot了。
b
bigjohn123456
https://www.wsj.com/articles/moderna-developing-vaccine-booster-shot-against-virus-strain-first-identified-in-south-africa-11611581400?mod=hp_lead_pos1 Moderna Developing Vaccine Booster Shot Against Virus Strain First Identified in South Africa
是不是也说明,另一方面也说明这病毒最后很可能就是应对流感的对付方法,疫苗每年,甚至每几个月改一下? 人类刚开始会抵抗,最后会逐步放弃抵抗跟新冠共存。
g
gourdcn
共存可能是必须的吧。我要求不高,只要能像流感就行了
s
surge
这是个好消息。而且今天拜登政府说要对南非impose travel ban。现在可能已经晚了,不过better than nothing. 我实在搞不懂这个南非的变种早就在讨论了,为啥这个travel ban 不早点实施。欧洲的travel ban 影响还大,这个南非断了也就断了,早断早好啊
a
andyconnor
这是个好消息。而且今天拜登政府说要对南非impose travel ban。现在可能已经晚了,不过better than nothing. 我实在搞不懂这个南非的变种早就在讨论了,为啥这个travel ban 不早点实施。欧洲的travel ban 影响还大,这个南非断了也就断了,早断早好啊
surge 发表于 2021-01-25 10:22

也不看看之前谁在台上,疯王下台前最后一天还莫名取消了所有covid相关travel restrictions, 拜登上台一周内能恢复而且加了个南非已经很不错了
l
little_racoon
回复 7楼bigjohn123456的帖子
前几年估计每年都要打针对新突变的booster shot。不过有一种可能是同时具有高传染性和高致病性的变种是有限的,病毒演化出了所有可能的突变之后一针多价疫苗可以提供好几年的保护。
C
CleverBeaver
不会吧?已经说要做针对南非变异的新型号了
Z
ZYL
谢谢分享信息
f
francesjj
这是个好消息。而且今天拜登政府说要对南非impose travel ban。现在可能已经晚了,不过better than nothing. 我实在搞不懂这个南非的变种早就在讨论了,为啥这个travel ban 不早点实施。欧洲的travel ban 影响还大,这个南非断了也就断了,早断早好啊
surge 发表于 2021-01-25 10:22

我真觉得政策制定者应该每天来华人蹲点,这样可以更快发现很多苗头。感觉基本华人上的传闻,过一阵都成更真的了。
糯米烧卖
回复 7楼bigjohn123456的帖子
前几年估计每年都要打针对新突变的booster shot。不过有一种可能是同时具有高传染性和高致病性的变种是有限的,病毒演化出了所有可能的突变之后一针多价疫苗可以提供好几年的保护。
little_racoon 发表于 2021-01-25 11:13

浣熊MM,我听过一个说法,就是这种病毒为了保证与ACE2的结合,所以变异逃逸的能力有限。以后会有疫苗能覆盖各种毒株。我不是你们专业的,请教一下是不是真的?
u
underdoc
回复 7楼bigjohn123456的帖子
前几年估计每年都要打针对新突变的booster shot。不过有一种可能是同时具有高传染性和高致病性的变种是有限的,病毒演化出了所有可能的突变之后一针多价疫苗可以提供好几年的保护。
little_racoon 发表于 2021-01-25 11:13

我担心会有original antigenic sin问题 打了booster,但是加强的是既认识野生型又认识突变型的克隆。。。。
s
surge
有没有辉瑞疫苗对新变种的研究?
一粒橘子
不知道等到了夏天,大家都能打上疫苗的时候,现有的疫苗还有没有用了😅
l
lyksj
好消息
另外,也期待J&J的疫苗上市
l
little_racoon
回复 16楼underdoc的帖子
是的,等他们clinical trial的结果吧。。。说不定booster shot可以只用新突变的RBD部分做?
d
drugdealer
不知道等到了夏天,大家都能打上疫苗的时候,现有的疫苗还有没有用了😅
一粒橘子 发表于 2021-01-25 20:27

不要忘了一个基本的道理:病毒mutation是在繁殖过程中出现的。因此传染的人,繁殖量越少,新出现的mutation就会越少。 所以要大家都打疫苗,让这种突变每几年十几年才出现一次。
s
syqhsdc
回复 6楼little_racoon的帖子
小浣熊MM,有没有关于T细胞免疫的比较全面的review你比较推荐的?比如提到了T细胞免疫如何避免重症之类的内容,谢谢哈